Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.35 |
| ▸ | ACACA | Q13085 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18964399 | 0.89 | ACACB (0.41) | SLC6A2SLC6A4ACACBHTR2AHTR2C | |
| SCHEMBL18959753 | 0.89 | SLC6A2 (0.40) | SLC6A2SLC6A4ACACBHTR2AHTR2C | |
| SCHEMBL18908179 | 0.87 | ACACB (0.48) | SLC6A2SLC6A4ACACBHTR2AHTR2C | |
| SCHEMBL18908180 | 0.86 | ACACB (0.42) | SLC6A2SLC6A4ACACBHTR2AHTR2C | |
| SCHEMBL18959743 | 0.86 | ACACB (0.38) | SLC6A2SLC6A4ACACBHTR2AHTR2C | |
| SCHEMBL18959741 | 0.78 | KDM4E (0.38) | SLC6A2SLC6A4HTR2AHTR2C | |
| SCHEMBL18961581 | 0.77 | PTGDR2 (0.33) | SLC6A2SLC6A4ACACBHTR2CACACA | |
| SCHEMBL18914372 | 0.77 | ACACB (0.42) | SLC6A2SLC6A4ACACBHTR2AHTR2C | |
| SCHEMBL18959737 | 0.76 | HTR2A (0.38) | SLC6A2SLC6A4HTR2AHTR2CSMN1; SMN2 | |
| SCHEMBL21231882 | 0.75 | ACACA (0.40) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166582-A1 | PYRAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| US-20170166583-A1 | ESTER ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166583-A1 | ESTER ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | SLC6A2 4204/4885SLC6A4 4185/4885ACACB 2/4885 |
| US-20170166582-A1 | PYRAZOLE ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, PC | SLC6A2 4478/4885SLC6A4 4246/4885ACACB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.